Pacira BioSciences: FY2023 revenue $675M (+1% YoY), net income $42M; CFO to leave Sept 30

Pacira BioSciences, Inc.

2023-FY EPS reported $0.89 revenue$674,978,000

Q4 revenue $181.2M (+5% YoY), GAAP net income $24.9M ($0.54 basic EPS), adj EBITDA $65.4M.
Full-year 2023 total revenue $675.0M (+1% YoY), GAAP net income $42.0M ($0.91 basic EPS), adj EBITDA $214.5M.
CFO Charles Reinhart to depart effective Sept 30, 2024; transition services through June 2025; search for successor underway.
2024 guidance: total revenue $680M-$705M; non-GAAP gross margin 74%-76%; R&D $70M-$80M; SG&A $245M-$265M.
FDA approved new 200L EXPAREL manufacturing suite in Feb 2024; expects commercial product later this year to benefit gross margins.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles A. Reinhart, III

Chief Financial Officer

PCRX · Pacira BioSciences, Inc.

Effective: 2024-09-30
Filed: February 29, 2024, 6:59 PM ET

On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024 (the “Transition Date”).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue $675.0 million, net income $42.0 million, EPS $0.91 per basic share and $0.89 per diluted share.

Period: fourth quarter and full-year ended December 31, 2023
Revenue: $675.0 million
Net income: $42.0 million
EPS: $0.91 per basic share and $0.89 per diluted share
Result: reported results

Exact text from the filing

a filing. --- EX-99.1 (EX-99.1) --- NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..

Action: will depart
Role: Chief Financial Officer

Exact text from the filing

On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024 (the “Transition Date”).

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-24-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.